U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Slexipag (Uptravi) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Cover of Clinical Review Report: Slexipag (Uptravi)

Clinical Review Report: Slexipag (Uptravi) [Internet].

Show details

APPENDIX 4Detailed Outcome Data

Figure 2Disposition of Patients in Griphon

Redacted at the request of the manufacturer.

Source: Clinical Study Report.8

Figure 3. Time to Death up to Study Closure.

Figure 3Time to Death up to Study Closure

Note: Bars on the graph show 95% confidence intervals of the estimates. Death with onset date up to 16 Aug 2011 are included as death.

CI = confidence interval.

Source: Clinical Study Report.8

Figure 4. Absence of Worsening in Functional Class from Baseline to Week 26.

Figure 4Absence of Worsening in Functional Class from Baseline to Week 26

FC denotes WHO functional class.

* Missing data at week 26 were included in the analysis as worsening.

CI = confidence interval; FC = functional class; vs. = versus; WHO = World Health Organization.

Source: From N Engl J Med. Sitbon 0, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. 373(26), p.2522-33 Copyright © (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society,

Figure 5. Primary Composite End point by Subgroup.

Figure 5Primary Composite End point by Subgroup

CI = confidence interval; ERA = endothelin receptor agonist; HPAH = heritable pulmonary arterial hypertension; IPAH = idiopathic pulmonary arterial hypertension; PAH = pulmonary arterial hypertension; PDE5 = phosphodiesterase type 5; WHO = World Health Organization.

Source: From N Engl J Med, Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. Supplementary appendix. 373(26), p.2522-33 Copyright © (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Figure 6Absolute Change from Baseline to Week 26 in Six- Minute Walk Distance at Drug Trough: Exploratory Subgroup Analyses from the Griphon Trial

Redacted at the request of the manufacturer.

Source: Clinical Study Report.8

Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK533861
Contents

Views

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...